Biogen, Eisai’s Alzheimer’s Drug E2609 to Enter Late-Stage Trial

Japan’s Eisai Co. said that an Alzheimer’s drug it is developing with Massachusetts-based Biogen Inc. will enter late-stage trials after getting the green light from the U.S. Food and Drug Administration.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.